The firm said that it will use proceeds from the sale to purchase or repay other notes or loans, including up to $300 million in outstanding senior notes.
The Finnish company also announced that it has received CE-IVD marking for its Aiforia Clinical pathology image analysis platform.
The study, sponsored by the US Centers for Disease Control and Prevention, focused on men who have sex with men and members of their social networks.
PTC Therapeutics is developing a gene therapy for the rare genetic disease AADC deficiency, which impacts the production of two key neurotransmitters.
BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.
The firm said it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.
The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.
The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen.
The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.
News items for the week of Nov. 11, 2019.